Medullary Thyroid Cancer - Pipeline Insight, 2025

This “Medullary Thyroid Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Medullary Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Medullary Thyroid Cancer: Understanding

Medullary Thyroid Cancer: Overview

Medullary thyroid cancer, or MTC, is a cancer that forms in the thyroid. The thyroid is a gland located in the front of neck, just below the Adam’s apple. It is responsible for sending out hormones to the rest of body. The inside of the thyroid is called the medulla. The medulla contains special cells called para follicular C cells that produce and release hormones. MTC happens when the C cells become cancerous and grow out of control. MTC may also be called medullary thyroid carcinoma. Thyroid cancer is fairly common. There are four different types of thyroid cancers and MTC is the rarest type making up 3% to 4% of all thyroid cancers. About 1,000 people are diagnosed with MTC each year in the U.S. MTC can start as a lump in the throat. The tumor growing in the thyroid can make voice hoarse by blocking vocal chords or it can make it hard to breathe by blocking windpipe.Medullary thyroid cancer can, and frequently does, spread (metastasize) to lymph nodes (in lymphatic system) and other organs, including lungs, liver, bones, brain, signs and symptoms of medullary thyroid cancer (MTC) includes a nodule (lump) on the upper part of thyroid gland (75% to 95% of people have this at diagnosis),swollen lymph nodes (lymphadenopathy) in neck (70% of people have this at diagnosis) an enlarged thyroid nodule, which can cause hoarseness, difficulty swallowing or breathing issues (this is less common),and in some cases, people have MTC for a long time before they notice symptoms because the tumor remains small.

Medullary carcinoma of the thyroid constitutes approximately 4% to 10% of all thyroid cancers in the United States. As opposed to the sporadic medullary thyroid cancer which is usually unilateral, the medullary thyroid cancer associated with multiple MEN syndromes is usually multicentric and bilateral. Often these tumors involve the upper portions of both lobes because the C cells reside predominantly in the upper poles of the thyroid gland. Paraneoplastic syndromes like Cushing syndrome and carcinoid syndrome can occur as medullary thyroid cancer, and can also produce hormones such as corticotropin, serotonin, prostaglandins, and melanin.Medullary thyroid cancer usually presents as a lump or nodule on thyroid gland. It may notice it or healthcare provider may discover it during a routine neck examination. Sometimes, the nodule is discovered incidentally (accidentally) by imaging tests get for other medical reasons. Imaging tests, fine needle aspiration (needle biopsy), and blood tests. The main treatment for MTC is surgery to remove entire thyroid gland (total thyroidectomy).

Treatment of MTC has other than surgery, the healthcare provider may recommend other treatments, includes Radiation therapy, Chemotherapy, Targeted therapies that act on changes in DNA found in some cases of MTC. MTC is usually more aggressive than the other more common types of thyroid cancer. It’s usually easier to treat and manage if it’s found before it spreads to lymph nodes in neck or other parts of body. Many people develop medullary thyroid cancer (MTC) for no known reason (known as sporadic cases), so prevention isn’t possible.

'Medullary Thyroid Cancer - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medullary Thyroid Cancer pipeline landscape is provided which includes the disease overview and Medullary Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Medullary Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medullary Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Medullary Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Medullary Thyroid Cancer.

Medullary Thyroid Cancer Emerging Drugs Chapters

This segment of the Medullary Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Medullary Thyroid Cancer Emerging Drugs

Regorafenib: Bayer HealthCare

Regorafenib is an oral, small-molecule, multi-kinase inhibitor developed by Bayer HealthCare that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (RET, RAF, and KIT). It was originally developed for the treatment of metastatic colorectal cancer. Regorafenib blocks several kinase proteins that either help tumor cells grow or help form new blood vessels to feed the tumor. Blocking these proteins can help stop the growth of cancer cells. The drug is under Phase II stage of development as an oral tablet formulation for the treatment of Medullary Thyroid Cancer (MTC). Currently, the drug is in Phase II stage of its development for the treatment of Medullary Thyroid Cancer.

TY-1091: TYK Medicines, Inc

TY-1091 as a novel next-generation RET inhibitor through the in-house RET program and systemic screening of RET compound candidates. TY-1091 was characterized for its anti-tumor activity through in vitro and in vivo testing of a variety of RET-dependent tumor models including a panel of 17 engineered RET mutant Ba/F3 cell lines and 2 cancer cell models.Currently, the drug is in Phase I/II stage of its development for the treatment of Medullary Thyroid Cancer.

APS-03118: Applied Pharmaceutical Science

APS03118 is the next-generation of selective RET inhibitor that independently developed by APS. APS03118 is a potential best-in-class program with stronger anti-tumor activity and better tolerability compared to other RET inhibitors in preclinical internal head-to-head studies. At present, APS03118 clinical trials has been approved by FDA and NMPA. Currently, the drug is in preclinical stage of its development for the treatment of Medullary Thyroid Cancer.

Medullary Thyroid Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Medullary Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Medullary Thyroid Cancer

• There are approx. 8+ key companies which are developing the therapies for Medullary Thyroid Cancer. The companies which have their Medullary Thyroid Cancer drug candidates in the most advanced stage, i.e. phase II include, Bayer HealthCare

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Medullary Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Medullary Thyroid Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medullary Thyroid Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medullary Thyroid Cancer drugs.

Medullary Thyroid Cancer Report Insights

• Medullary Thyroid Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Medullary Thyroid Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Medullary Thyroid Cancer drugs?
• How many Medullary Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medullary Thyroid Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medullary Thyroid Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Medullary Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bayer HealthCare
• TYK Medicines, Inc
• Applied Pharmaceutical Science
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd

Key Products

• Regorafenib
• TY-1091
• APS-03118
• HA121-28

This product will be delivered within 2 business days.